Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421 PHASE2 COMPLETED

This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	COMPLETED
Enrolment	71
Start date	Thu Sep 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Dyskinesias
• Drug-induced

Interventions

• AQW051
• AQW051
• Placebo

Countries

France, United States, Germany, Italy